New fully human monoclonal antibody or monoclonal antibody fragment is a bispecific antibody or an immunoconjugate, used in pharmaceutical composition and manufacture of pharmaceutical composition against Coronaviruses for treatment, prevention or diagnosis of Coronaviruses
	SYED S; AHMED S S; PIDIYAR V; AHMED K
	2023-12-11
专利权人	TECHINVENTION LIFECARE PRIVATE LTD (TECH-Non-standard)
申请日期	2023-12-11
专利号	IN202321084177-A
成果简介	NOVELTY - Fully human monoclonal antibody or monoclonal antibody fragment is new, where human monoclonal antibody or monoclonal antibody fragment is a bispecific antibody or an immunoconjugate having 90% identity to sequences comprising defined amino acid sequences of (SEQ ID NOs: 1-16), given in the specification. USE - Fully human monoclonal antibody or monoclonal antibody fragment used in pharmaceutical composition and manufacture of pharmaceutical composition against Coronaviruses for treatment, prevention or diagnosis of Coronaviruses, where Coronaviruses are selected from severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus 2 (MERS-Cov), or severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2), or combination, preferably SARS-Cov-2 (all claimed). No biological data given. ADVANTAGE - The fully human monoclonal antibody or monoclonal antibody fragment is capable of neutralizing multiple variants of Coronavirus infectivity, and treat Coronaviruses in more economical, and easy manner, and fulfils the unmet medical need for Coronavirus disease 2019 (COVID-19) prophylaxis and treatment. DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for: Pharmaceutical composition, which comprises the antibody and a pharmaceutically acceptable carrier; and Method of producing a fully human Monoclonal Antibody to target coronavirus spike (s) glycoprotein or receptor binding protein, which involves: (1) collecting blood; (2) isolating RNA; (3) carrying out complementary DNA (cDNA) conversion and monoclonal antibody genes amplification by polymerase chain reaction (PCR); (4) cloning monoclonal antibody Genes and banking single-chain variable fragment (scFv) library; (5) carrying out monoclonal antibody selection by bio-panning; (6) screening by enzyme-linked immunosorbent assay (ELISA); (7) performing DNA sequencing and expression and purification in immunoglobulin G (IgG).
IPC 分类号	A61K-039/00 ; A61P-031/14 ; A61P-035/02 ; C12N-015/86 ; C12Q-001/70
国家	印度
专业领域	医药卫生
语种	英语
成果类型	专利
文献类型	科技成果
条目标识符	http://119.78.100.226:8889/handle/3KE4DYBR/18978
专题	中国科学院新疆生态与地理研究所
作者单位	TECHINVENTION LIFECARE PRIVATE LTD (TECH-Non-standard)
推荐引用方式 GB/T 7714	SYED S,AHMED S S,PIDIYAR V,et al. New fully human monoclonal antibody or monoclonal antibody fragment is a bispecific antibody or an immunoconjugate, used in pharmaceutical composition and manufacture of pharmaceutical composition against Coronaviruses for treatment, prevention or diagnosis of Coronaviruses. IN202321084177-A[P]. 2023.

条目包含的文件
条目无相关文件。

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。